Intravenous (IV) Solution Market Highlights :

The global IV solutions market is expected to register a CAGR of 7.69% during the forecast period and is expected to hit USD 11,511.2 million by 2028.

Intravenous therapy delivers fluids, medications and nutrition directly into a patient's vein. The intravenous route is commonly used to provide nutrition or for rehydrationtopatients who unable toingest food or water by mouth.

Growing prevalence of chronic diseases, rapidly growing population prone to dysphagia, and innovations in IV solutions market are driving the growth of the IV solutions market. Additionally, rising product launches by major market players are also driving the growth of the IV solutions market.

For instance, Otsuka Pharmaceuticals (Japan) launched an ENEFLUID injection, the first peripheral parenteral nutrition solution that containswater-soluble vitamins and fat in addition to glucose, amino acids, and electrolytes in a dual-chamber bag.Similarly, in April 2019, B. Braun Melsungen AG (Germany) announced the launch of its Heparin Sodium Injection, USP, with attached safety needle for subcutaneous and intravenous use in the US.However, stringent government regulationsareposing a challenge for the growth of the market. For example, theUS-based company voluntarily recalled one single lot of Lactated Ringer's Injection, USP, in May 2020. The products were being recalled to the hospital/user level due to the presence of particulate matter identified as iron oxide.


Intravenous (IV) Solution Market Segment Analysis :

The global IV solutions market has been dividedbased on nutrition type, bag type, nutritional content,and end user. The market, based on nutrition type, has been bifurcatedinto peripheral parenteral nutritionand total parenteral nutrition.

Based on bag type, the IV solutions market has been bifurcated into large volume bags (>250 ml)and small volume bags (